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After many years on the periphery of cancer therapy, the successes of proton and ion beams in tumor
therapy are gradually receiving a higher degree of recognition. The considerable construction and
acquisition costs are usually invoked to explain the slow market penetration of this favorable treatment
modality. Recently, high-intensity lasers have been suggested as a potential, cost-saving alternative to
cyclotrons or synchrotrons for oncology. This article will detail the technical requirements necessary for
successful implementation of ion beam therapy (IBT)—the general term for proton and heavier-ion
therapy. It will summarize the current state of laser acceleration of protons and will outline the very
substantial developments still necessary for this technology to be successfully applied to IBT.
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I. INTRODUCTION
Sixty years after Robert Wilson’s initial proposal to use
fast protons for radiotherapy [1], the physical advantage of
the Bragg peak inherent in slowing protons and ions is
undisputed. However, despite encouraging results and
about 50 000 patients treated, IBT still leads a niche sub-
sistence in cancer therapy (for reviews, see [2– 4]). High
capital costs of proton-therapy installations—and even
higher costs for carbon-ion facilities—are most often cited
as the primary hurdles to more widespread application.
Recently, IBT has been receiving unexpected promotion
from researchers of the high-power laser community [5–
12]. These authors typically state that the use of ultra-
intense lasers rather than conventional particle accelerators
could provide ‘‘compact, flexible and cost-effective’’ ther-
apy facilities, fostering the propagation of IBT. Several
authors imply that the technology is quite close to being
ready for direct application in the field [9].
Lest untimely promises be made and the medical com-
munity prematurely rush to this new and exciting technol-
ogy, we wish to point out some very substantial hurdles still
facing laser accelerators before this technology can be
successfully applied to generating ion beams adequate
for radiotherapy in human patients. To do this, we will
discuss in depth the very exacting beam requirements to
ensure optimal deposition of the prescribed dose, allow
accurate dosimetry and verification of dose delivery, mini-
mize the dose to areas outside the desired treatment vol-
ume, and assure patient safety from accidental overdoses.
It should first be stated quite categorically that it has
taken years and decades for conventional accelerators to
achieve the above beam qualities that ensure the present
success of IBT. As will be pointed out, the task of lasers to
match the capabilities of conventional accelerators in this
field is a truly huge one, and practitioners in the field must
not be tempted to lose sight of the tremendous task at hand
before making misleading claims that can raise expecta-
tions within the medical community.
II. BACKGROUND: DEVELOPMENT AND
CURRENT STATE OF IBT
The search for higher precision and greater antitumor
effectiveness has been the driving force in the history of
radiotherapy. After the discovery of the favorable depth-
dose profile of protons and other ions by Robert Wilson at
what later became the Lawrence Berkeley Laboratory
(LBL) in Berkeley, USA [1], it only took a few years until
the first clinical application. It was John Lawrence who
used protons from the LBL cyclotron for pituitary hormone
suppression in patients with metastatic breast carcinoma
[13]. Functional stereotactic radiosurgery in the brain and
fractionated proton therapy of large tumors were soon to
follow in Uppsala, Sweden, and at the Harvard Cyclotron
Laboratory in conjunction with the Massachusetts General
Hospital in the USA. Until 1990, when the first hospital-
based proton therapy center opened its doors in Loma
Linda, California, IBT was only offered in 10 physics
laboratories around the world (for a review on the early
history on IBT cf. [14]). Today, the number is up to 27,
with 11 facilities being hospital based. Three more clinical
IBT centers will become operative within the next
12 months and at least six more have been commissioned.
Approximately 50 000 patients have been treated with
ion beams, the vast majority ( > 90%) with protons.
During the first decades relatively rare diseases were
treated for which there were no real alternatives (e.g.,
arteriovenous malformations, uveal melanomas, chordo-
mas, chondrosarcomas). At present IBT is used to treat
tumors in nearly all parts of the human body (for recent
reviews, see [3,4,15]).
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Although IBT has been available for more than 50 years,
it is still a relatively uncommon treatment modality. Many
technological advances of the past 30 years were necessary
to make full use of the favorable physical characteristics of
ion beams. Prior to the advent of computer tomography,
e.g., tumor imaging and localization did not permit reso-
lution in the millimeter range. As a consequence, dose
volumes had to be kept much larger than medically neces-
sary and technically feasible by IBT. Therefore, the supe-
rior dose distribution of ions could not be fully exploited at
that time. Magnetic resonance imaging, new developments
in beam delivery, and computing have all helped to make
better use of the physical properties of ions.
The fact that IBT was initiated in physics laboratories is
probably another reason for its slow spread. Beam time for
medical applications was limited in these laboratories and
often had to be shared with the nuclear physics programs.
As the institutions were lacking the most basic clinical
environment, the patients had to be able to tolerate the
treatment sessions without too much assistance and clinical
support. This made patient recruitment difficult and re-
stricted the treatable diseases to indications for which there
were no real alternatives.
Gradually, it became recognized that IBT yields results
which can compete with the most advanced x-ray tech-
niques, even though the treatment conditions in most cen-
ters are still suboptimal (e.g. fixed beam direction,
mechanical beam spreading). Advances such as beam
scanning, respiration gating, intensity modulation, etc.,
make ion beams even more attractive for therapy, enabling
full exploitation of the physical advantages and reduction
in the irradiated volume to only what is clinically neces-
sary. Industry, which ignored the field for many years,
seems to recognize IBT as well as an upcoming market.
There are now several companies which offer turnkey IBT
units (IBA, Siemens, Varian/Accel, Hitachi, Mitsubishi,
and Optivus).
III. BEAM REQUIREMENTS FOR IBT
Producing beams of high-energy particles is accom-
plished by many types of accelerators, including now
high-power lasers. However, a raw beam is a powerful
and highly dangerous tool; it must be carefully shaped
and controlled before it can be safely and effectively
used for radiation therapy (RT). In addition to the control
of transverse dose distribution (lateral field shaping) re-
quired for x-ray RT, IBT has—because of the Bragg
peak—the need to accurately control the stopping point
of the beam. This added dimension contributes to the
complexity of IBT.
In the following we will outline the specific character-
istics of ion beams necessary to produce well-defined and
effective radiation fields. We will describe a specific re-
quirement, how this is met with current-technology accel-
erators, and the present state of laser-driven accelerators in
this area.
IV. BEAM ENERGY
The 25 to 30 cm range in tissue is viewed as the most
basic requirement for an ion beam. This translates to 200 to
225 MeV protons, and 400 to 430 MeV=amu carbon ions.
This energy must be available at the surface of the patient,
so if beam spreading or shaping techniques are employed
that require passing the beam through material, the primary
energy from the accelerator must be increased further to
compensate for energy lost in these devices.
A. Status: Conventional accelerators
Compact normal-conducting proton cyclotrons of
235 MeV are approximately 4 meters in diameter, super-
conducting cyclotrons can be somewhat smaller.
Proton synchrotrons of 250 MeV are larger, approxi-
mately 10 meters in diameter, but are much less massive
and overall are more efficient in beam utilization. All of
these accelerator types are now commercially available as
‘‘turnkey’’ clinical facilities from major manufacturers,
with beam-delivery systems and fully-tested control sys-
tems. They have been thoroughly reviewed and approved
by national health-management organizations [16].
Carbon-ion beams of the required energy are best produced
with synchrotrons; the higher energy and rigidity of these
beams require considerably larger rings, typically 20–
25 meters in diameter. Three such facilities dedicated to
IBT are operating today. Several more are being built and
will be operational in coming years [17].
B. Status: Laser accelerators
The highest published energy obtained for protons is
58 MeV, with a very large high-power, high-energy laser
system at the Lawrence Livermore National Laboratory
[18]. The smaller lasers being highlighted as the precursors
of the technology path proposed for medical applications
have not produced protons higher than about 10 MeV.
The excitement in the field has come from the advances
allowing production of extremely short pulses, condensing
the energy from modest lasers into extremely high instan-
taneous power. Thus, instead of kilojoule lasers with pico-
second pulses (such as used for the above-cited 58 MeV
experiment), lasers with a few joules can produce, by use
of pulse-compression ‘‘chirping’’ techniques, femtosecond
pulses in the 10–100 terawatt range. There is a clearly
defined correlation between the instantaneous power in the
laser-pulse striking a solid target and the energy of protons
accelerated from the back side of this target. Modeling
studies and scaling extrapolations indicate that an increase
of laser energy by about a factor of 10, with the same or
slightly improved pulse-compression techniques, could
produce protons of 200 or more MeV [10]. It is assumed
that developments in the next few years should yield
commercially available lasers of the required energy.
However, the major step remains to verify the scaling
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laws over such a large extrapolation. The physical systems
are highly complex with instabilities and uncertainties. It is
by no means certain that placing the higher-power pulse on
the target will lead to the desired energy of protons at the
required flux.
V. ENERGY VARIABILITY AND
MONOCHROMATICITY
The basic 1=E dependence of the energy loss curve of an
ion beam implies that producing the desired dose at every
depth of the treatment field requires extremely precise
control over the energy of the beam, and of the flux at
each energy level. Treatment planning will ultimately de-
convolve a dose in each voxel of the treatment volume to a
flux at each lateral fx; yg coordinate, and an energy spec-
trum to yield the correct dose as a function of depth fzg.
This implies control of the energy distribution of pulses at
each fx; yg coordinate to within a few percent. Range
straggling and multiple scattering limit the accuracy of
dose deposition, but appropriate treatment planning can
take these into account and still obtain dose distributions
within a few percent and dose falloffs of a few millimeters.
A. Status: Conventional accelerators
Energy spread of a beam emerging from the above-
mentioned accelerators will be of the order of 0.1%
E=E. This is a regular property of accelerators of this
type. Any higher energy spread would cause too much
beam loss inside the accelerator, and almost no beam
would reach the final extraction energy. This very narrow
energy spread also provides for efficient beam transport
from the accelerator through the highly complex gantry
transport system, which allows the beam to enter the
patient from almost any angle. The high precision of the
beam energy warrants that the final width of the Bragg
peak is not impaired beyond the contribution of range
straggling [19,20].
Energy variability is slightly more complicated. With a
synchrotron, it is possible to flattop the magnetic field at
the desired energy and extract the pulse at this energy, so
each cycle of the synchrotron can produce a beam of
protons or ions of a different energy, over the full pre-
scribed range for the treatment. Pulses of the desired en-
ergies are superimposed to produce the required depth-
dose profile in a tightly controlled fashion.
Obtaining the necessary depth-dose profile with a cyclo-
tron beam is more complex since the beam emerges always
with the same energy from the accelerator. To produce
lower-energy beams, the protons are passed through an
energy-degrader system consisting of a variable-thickness
foil, and a magnetic spectrometer and collimation system.
Though substantial angular spread is introduced due to
scattering in the foil, the collimators select the beam
emittance necessary to be transmitted to the patient.
Sufficient intensity reserve is available in the cyclotron to
compensate the beam loss and to ensure a satisfactory dose
rate at the patient. The result of this process is the same
very tightly controlled dose-energy profile of the beam
delivered to the patient.
Early accelerator systems that lacked the sophisticated
energy-variability techniques now available were still able
to achieve relatively good depth-dose distributions using
monochromatic beams and wedge or ridge filters as part of
the final beam-delivery system [20]. Though still employed
in many IBT installations, this technique does not give the
best dose distributions IBT is capable of. As scanning
systems come into wider use, these devices are being
phased out.
B. Status: Laser accelerators
Unfortunately, the proton pulses from a laser target are
far from monochromatic. Usual energy spread is 100%,
with only a small fraction of the total flux at the highest
energy [9]. Progress is being made to improve this, with
shaped targets to maximize the proton flux in a narrower
forward cone [6,7]. A small dot of PMMA (polymethyl
methacrylate) or other proton-rich material on the back
side of the target, lining up precisely with the laser-pulse
center, can substantially increase the localization of emit-
ted protons to a well-defined area, where the electron-
blowoff field is at its highest uniformity. Best results to
date have yielded an energy spread of about 25% FWHM,
but still with considerable low-energy tails, and relatively
low proton flux [6].
As indicated above, accuracy in dose-delivery relies on
excellent control over the full range of energies required
for the treatment, and of the flux at each energy.
Controlling the maximum energy of protons from a laser-
pulse will require careful control over the power and
stability of the laser system, to a degree which appears
not to be within current operational experience [8,10].
Shot-to-shot tunability, reproducibility, and predictability
must be improved to a level of a few percent! If, in
addition, micron accuracy is required for the positioning
of microdots in a target to line up precisely with the center
of the laser pulse, at a high repetition rate, the problems
become more difficult to solve.
One method for ensuring safe, reliable operation of such
a system would be to place the laser accelerator at the same
location of the present cyclotron or synchrotron, to use the
very restrictive beam transport system to allow only the
particles of the right characteristics to be transported to the
treatment room. However, this would completely defeat
the basic premise of compactness of the new technology,
and would almost surely not be capable of adequate dose
rates. Designing energy-selection spectrometers suitable
for use with laser systems is proposed by several authors
[21,22], however, the large divergence of the beams and
high rigidity makes such spectrometers extremely difficult
to design properly, as well as quite large; interfacing these
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with a patient delivery system would create a device not
unlike the size of the present-day gantries.
If one looks at the energy spectrum of an actual beam
used in therapy, the so-called ‘‘spread-out Bragg peak’’
(SOBP), it does indeed have a very large energy spread.
One might argue that this is not so unlike the energy spread
from a laser-accelerator pulse. Indeed, if the maximum
energy of the protons were reproducibly and reliably con-
trollable, and if the pulse-to-pulse energy spectrum were
controllable and reproducible to within a few percent, it
would probably be possible to design a mechanical filter,
akin to those used in the early days of IBT, to adjust the
spectrum from this pulse to the desired spectrum for a
given SOBP. These stability and controllability require-
ments are very likely difficult challenges for the laser
accelerator, and as indicated above would only produce a
technology that is a generation behind the scanning
technique.
VI. BEAM INTENSITY
Treatment times must be kept to a maximum of a few
minutes. Immobilization issues, patient comfort, but also
‘‘customary practice’’ with current RT technologies indi-
cate that longer treatment times would render new tech-
nologies unattractive and uncompetitive. A treatment of an
average volume of approximately 1 liter to a dose of 2 Gy
in 1–3 minutes requires of the order of 1012 protons,
translating to about 1010 protons per second as the required
flux at the treatment site.
A. Status: Conventional accelerators
1010 protons per second corresponds to about 2 nano-
amperes of continuous beam. Normal cyclotrons can pro-
duce beams of many microamperes, specialized ones even
in the milliampere range. The required fluxes are, there-
fore, easily obtainable. They are also adequate to be de-
tected by normal beam-diagnostic instrumentation, so
control and feedback of the accelerator parameters are
easily achieved.
Synchrotrons can easily capture and accelerate 1010
protons in an acceleration cycle, and with a cycle rate of
about 0.5–0.3 Hz can match quite closely the requirements
for IBT. Well-designed and tuned synchrotrons in this
energy range can accelerate and extract 10–100 times
this amount of beam. Pulse-to-pulse energy variability
and beam-current control enable excellent contouring of
the energy and dose profile to the required delivery
prescription.
B. Status: Laser accelerators
Published data on total proton flux from a single pulse
are from around 109 protons for a broad spectrum [10] to
108 protons from a shaped target with a peak energy well
below 10 MeV [6]. Achieving the required flux of 1010
protons per second will require a repetition rate of at least
10 Hz. The current generation of lasers is in principle
capable of this, but most of the literature describes experi-
ments at very low repetition rates. The next generation of
lasers, predicted to produce protons of the required energy,
is also advertised to be able to operate at 10 Hz. It is
essential that these new laser systems at least match the
protons-per-pulse performance of today’s systems.
It should be remembered that the 1010-protons=s speci-
fication is at the site of the patient, not at the exit of the
accelerator. In the case of conventional accelerators and
modern scanning systems, almost 100% of the beam, once
energy selected and formed, can be transported and used in
the treatment field. It is not clear what the efficiency of
proton utilization with laser accelerators can be to ensure
conformation to a prescribed treatment dose distribution.
The implication of this is that the required flux from the
laser systems should be substantially higher than
1010 protons= sec .
Finally, operating a laser accelerator at 10 Hz will
require very sophisticated target-handling and reaction-
chamber engineering, to ensure clearing of debris from
previous shots, and enabling the micron precision in target
positioning for shaped targets that will probably be neces-
sary [22,23].
VII. LATERAL FIELD DEFINITION
The greatest advantage of IBT is the ability to conform
the radiation field to very precisely defined contours of a
prescribed treatment volume. For truly parallel beams,
lateral dose falloff at the edge of the field is dominated
by multiple scattering in the patient. A well-designed IBT
delivery system will not contribute to this dose falloff
beyond what is physically possible. Lateral dose 90%-to-
10% falloff—or ‘‘penumbra’’—of about 1 cm at depth for
protons, and a few mm for carbon ions yields treatment
plans that are superior in sparing of tissue outside the
prescribed volume to the most sophisticated photon tech-
niques [2,24].
A. Status: IBT systems based on conventional
accelerators
Spreading the beam extracted from the accelerator by
passive scattering systems is simple and effective for pro-
ducing flat fields. But such systems increase the emittance
of the beam substantially, which leads to loss of precision
in lateral falloff by as much as a factor of 2 over the
physical limits.
The state of the art for IBT now employs magnetic
deflection of the pristine beams via a spot- or raster-
scanning system. The amount of matter the particles pass
through on their way to the patient is kept to an absolute
minimum. This maintains the excellent emittance of the
beam from the accelerator, yielding the lowest-possible
lateral penumbrae.
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B. Status: Laser accelerators
Protons from a laser accelerator all emerge from a spot
size about 1 m in diameter, at a typical divergence of
approximately half a radian or 23. Because of the
extremely small spot size, the transverse emittance,
fx g, is substantially smaller than the beam from
a conventional medical accelerator.
Such a beam could in theory be converted into a good-
quality pencil beam by a suitable beam transport system.
However, the transport system that will take a beam with
such a wide opening angle will be quite large and cumber-
some. In addition, most such systems are magnetic, and so
very sensitive to the energy of the particles, and the ex-
tremely high-energy spread of the raw beam from the laser
target would render the design of such a transport system
nearly impossible.
The longitudinal emittance of the laser-produced beams
is also phenomenally low, because of the small product of
the energy spread and the time width of the beam. As the
laser pulse is measured in tens of femtoseconds, even with
a 100% energy spread of a 10 MeV beam the longitudinal
emittance will be substantially smaller than that from a
conventional accelerator. In principle, by use of a
‘‘buncher’’ (a special-purpose radiofrequency accelerating
cavity), the narrow time width can be traded into reduced
energy spread. In simple terms, particles emerging from
the source at a higher energy reach the buncher placed a
distance away (typically a few meters) earlier than the
lower-energy ones, so if the accelerating gradient in the
buncher changes appropriately with time the high-energy
ones will be slowed while the slower ones are speeded up.
The practical problem is that bunchers work very well
when the energy spread is a small fraction of the total; in
the case of the high-energy spread of the ion beam from a
laser, the size and length of the buncher would match a full
conventional accelerator.
The bottom line is that, though the emittances of particle
bunches produced by laser acceleration are very favorable,
the hardware necessary to match these beams to a therapy
scanning system is unwieldy, expensive, and impractical.
But, does one need all these actions on the beam from
the laser accelerator to be able to use it for IBT? We have
indicated above that the number of protons in a given
element of the treatment volume, both stopping and tra-
versing, must be tightly controlled. It is difficult to see how
the energy spectrum, and the lateral distribution of the
plume from a laser target, can be made to correspond to
the prescription for each of the thousands of volume ele-
ments (voxels) in the treatment volume without a very
significant amount of control and modification.
VIII. DOSE CONFORMATION
The most desirable characteristic of a radiation therapy
modality is to be able to deliver radiation as close as
possible to the ideal envisioned by the radiation oncologist.
This usually means placing the optimal therapeutic dose
into the diseased area, and avoiding as much as possible
any irradiation of other areas of the body. One of the
biggest advantages of IBT is its potential to accomplish
this in a fashion superior to the most advanced photon
therapy techniques. The word ‘‘potential’’ is important
here because the key to achieving this goal lies in how
the particle beams are actually delivered to the patient. A
highly flexible source of particles, in which intensity, spot
size, position, and energy (depth) is finely controlled,
offers by far the greatest chance to meet this ideal.
Considering the rapid advances made with photon deliv-
ery such as intensity modulated radiation therapy, the true
advantages of IBT can only be realized with the most
sophisticated delivery systems offering maximum flexibil-
ity. Any source of protons that does not offer the same
flexibility to develop an optimized plan making full use of
the advantages of particles, will not be competitive with
conventional photon therapy.
A. Status: IBT with conventional accelerators
Cyclotrons (with external energy-selection systems),
and synchrotrons are capable of changing the energy of
the beam within seconds. The first scanning systems using
these conventional accelerator sources are already in rou-
tine use. Commercial vendors are on the verge of market-
ing fully integrated scanning systems. It is, therefore, fair
to say that conventional technologies are close to providing
the flexibility in beam parameters to ensure optimal deliv-
ery of charged particles [25,26].
B. Status: Laser accelerators
As described above, the energy spread and beam char-
acteristics expected for a laser-generated beam of protons
is quite far from the ideal monochromatic pencil beam. To
make use of the compactness of the laser systems, the
proton-producing target should be relatively close to the
treatment area and complex, heavy spectrometers should
not be used. Thus properly shaping and controlling the
laser plume before it reaches the patient will be difficult.
It is our view that with such a beam there is little hope that
an attractive treatment plan can be generated.
IX. DOSE ACCURACY AND DOSIMETRY
TECHNIQUES
Once a plan is made, it is important that the actual
delivery be carried out in a safe, accurate manner.
Specifically, the dose delivered to each voxel of the treat-
ment volume should match the prescription to within an
error of at most 5%. This is easily achieved by RT
technologies in use today with both photons and particles.
To achieve this, one must have a very high degree of
control over the accelerator and transport parameters, have
explicit trust in the reliability, accuracy, and reproducibility
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of these parameters, and, in addition, have reliable, accu-
rate dose-monitoring systems capable of verifying the
delivered dose and to quickly terminate a treatment when
anything unusual is encountered.
A. Status: IBT with conventional accelerators
In cyclotrons the beam emerges continuously and can be
controlled to an extremely precise degree. Synchrotrons
provide a ‘‘slow spill,’’ enabling a duty cycle of 25% to
50% and a relatively uniform beam during the extraction
time.
Accurate dosimetry is usually provided with ionization
chambers, whose response is linear as long as the instan-
taneous dose rate is not so high as to cause gas recombi-
nation. The continuous ion flux offers a safety factor.
Should an abnormality occur, the fast response time of
the ion chambers allows beam interruption to occur before
an unacceptably high dose has been delivered erroneously.
This is true even for the worst case of a pencil-beam
scanning system where beam is being concentrated in a
single voxel at the time the interruption is initiated.
B. Status: Laser accelerators
For an accelerator system which delivers beam in short
pulses, dosimetry values, including possible error condi-
tions, are recorded only after all the particles of a pulse
have entered the patient. The only condition in which this
type of operation will have an adequate degree of safety is
when the dose delivered in a single pulse is less than a few
percent of the total dose for the area treated. If one con-
siders a 10 Hz system, and a treatment time of 100 seconds,
there will only be 1000 pulses for a full treatment. If
treatment delivery is such that the whole field is irradiated
with each pulse, then an error with a single pulse will have
little consequence. However, the most optimized treatment
delivery techniques rely on sweeping small-dimension
beams, so that at any given instant only a small fraction
of the treatment volume is being irradiated [25,27]. Under
these conditions, a single pulse is important.
For instance, let us assume a treatment volume of 1 liter
divided into 1000 voxels of 1 cc. The delivery system
would have to provide the entire dose to a voxel in a single
pulse! In order to guarantee that a voxel is not overdosed or
underdosed, the flux in each beam pulse must be controlled
to the level of 5%. Considering the 50% reproducibility
quoted in the current laser-accelerator literature [6],
achieving this accuracy will be an ambitious task.
X. ISOCENTRIC DELIVERY
The vast majority of patients are treated in a supine
position. Not only does this provide maximum comfort
for the patients, improving immobilization, but it also
coincides with the position in which diagnostic scans are
taken. As precise knowledge of coordinates of organs,
target volumes, and other body structures is critical in
developing accurate treatment plans, it is imperative to
treat the patient in the same position in which the diag-
nostic scans are taken.
For greatest flexibility, optimal beam delivery is
achieved when the therapy beam can be aimed at the
supine patient from any angle in a vertical plane, while
freedom to rotate the patient about the vertical axis allows
not only full access to normal entry angles, but also oblique
ports, often invoked to avoid critical structures.
A. Status: IBT with conventional accelerators
Vendors of hospital-based proton-therapy systems now
offer gantry and patient-positioner systems that provide
flexibility of entry angles. The systems are large, heavy,
and expensive [28]. The situation is extreme for carbon
ions. For example, the isocentric gantry developed for the
Heidelberg facility weighs about 600 tons, has a diameter
of approximately 15 meters, and is 25 meters long [29]. In
addition, large expanses of concrete shielding are required,
as the gantry is located inside the vault of the treatment
room. It has been recognized that new designs are neces-
sary to reduce size and cost of this component of the beam-
delivery system [30].
B. Status: Laser accelerators
The possibility of bringing laser beams into the treat-
ment room and to redirect them with mirrors to a target that
can be rotated around a patient is truly attractive [9,11,22].
The key to successful application will be how close the
target can be placed to the patient, or how much room will
be needed for beam-forming and dosimetry systems to
ensure reliable, accurate, and effective treatments. The
worst possible scenario would be that beam-control hard-
ware for energy selection, focusing, and steering require
the proton source be far away, and the net size of this
hardware would not be that different from today’s conven-
tional gantries. At the present time, it is difficult to imagine
that this would not be the case.
XI. RADIATION PROTECTION,
ENVIRONMENTAL CONSIDERATIONS
Though the patient is receiving a significant radiation
dose, it is important to restrict this dose to the treatment
volume. Control of extraneous radiation sources is very
important.
A. Status: IBT with conventional accelerators
Beam transmission in the gantry transport system is
carefully monitored to minimize beam loss. Collimation
is provided to prevent scattered beam from reaching areas
of the patient outside the intended treatment zone. Beam
loss in these collimators and other areas will lead to
neutron production, to which the patient is exposed.
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Calculation and measurements indicate that dose from
these sources is an extremely small fraction of the treat-
ment dose [31].
B. Status: Laser accelerators
More than 40% of the laser energy is converted to
relativistic electrons, causing hard-x-ray bremsstrahlung
and neutrons [18,32]. In fact, neutron production is so
high that ultraintense lasers have been suggested as neutron
sources [33]. While probably not a problem of the same
magnitude as others previously discussed, shielding will be
another engineering issue that needs to be addressed.
XII. COST
The ion production and acceleration part, which the laser
technology challenges, comprises—depending on the
number of treatment rooms—10%–20% of the whole floor
plan and cost of a proton facility [19,34]. A cyclotron for
proton-therapy costs, currently, less than 10 106 Euros.
This is similar to the price quoted for a ‘‘compact’’ peta-
watt laser [35]. However, the cyclotron operates at only
200 kW, serves 3–5 treatment rooms, and lasts at least
30 years [19,36]. This clearly limits cost as a major argu-
ment in favor of laser-produced proton beams [5,11].
Reliability of the technology is preferred over prime
design with a high degree of innovation. Ease of operation
and fault tolerance are wanted. One example to illustrate
the attitude might be the application of superconducting
magnets. Despite the fact that weight and size could be
saved, this technology is only applied by one of the six
major manufacturers of IBT facilities.
Factors such as high beam availability (  95% of the
time,  12 h=d, 6 d=wk 48 wk=yr), infrequent, short
maintenance periods, and long lifetime of the equipment
do not only influence patient trust and acceptance. They are
essential for the amortization rate of the facility [19]. It is
hard to imagine how they could be mastered within the
next years, given the fact that the laser generation to
produce a therapeutic beam has not been put into practice.
XIII. CONCLUSIONS
The most important idea to be kept in mind is that
providing a source of 200 or 250 MeV protons is not
sufficient to make a successful IBT system. The interface
between the accelerator and the patient—the hardware and
software that effectively convert the beam from the accel-
erator into a radiation field suitable for therapy—are of
paramount importance.
The beam-delivery systems developed for the present-
day IBT configurations require incident particle beams that
have well-defined energy, very narrow energy spread, and
are tightly focused. These beam properties are not at all
what is found in particles accelerated by laser pulses, and
we have indicated that these accelerated protons cannot be
easily interfaced with the existing beam-delivery systems.
In addition to having to develop an entirely new tech-
nology for effective beam delivery and dose conformation,
the following challenges must be faced by the laser com-
munity: (i) verifying scaling laws for proton energy with
laser power, (ii) improving proton flux by at least an order
of magnitude, (iii) improving shot-to-shot reproducibility
to the few-percent level, (iv) development of suitable dose-
monitoring devices, (v) development of techniques for
accurate dose control and cutoff, and (vi) addressing
quality-assurance and patient-safety aspects. This is not
to say that one should not work towards solving these
tremendous problems! After all, it was realized over
100 years ago that orthovoltage x rays could be used for
treating malignancies, but it took many decades—plus the
development of a number of enabling technologies—be-
fore the concept became an effective medical technique.
The developments necessary for effective implementation
of laser-accelerated protons will possibly occur, but not
tomorrow, nor in the next few years. This technology will
not be able to replace conventional accelerators as an
effective tool in IBT anytime soon.
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